hotspot -WSS

hotspot

author：hotspot 2025-10-02 23:45:18 - browse：4477

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement comes just days after Eisai won final approval in the U.S. for its Alzheimer’s drug Leqembi.

Cheung will be replaced in his capacity as head of the Alzheimer’s unit by his brother-in-law Keisuke Naito, 34, who is currently chief ecosystem officer and chief strategy officer. He is also the son of Eisai CEO Haruo Naito.

Tatsuyuki Yasuno, current chief financial officer, will replace Cheung as head of Eisai’s U.S. unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

WSS

Donald Trump's relentless attacks on special counsel Jack Smith

In areas with more Black doctors, Black people live longer

How Robert F. Kennedy Jr. distorted vaccine science

Dexcom's push to bring CGM to type 2 diabetes patients

Disclosing genetic information: not as worrisome as once feared

Dexcom's push to bring CGM to type 2 diabetes patients

focus

hotspot

explore

ChatGPT in medicine: STAT answers readers' burning questions

WATCH: Why do fingernails fall off when they're damaged?

Hepatitis C has a cure — but many Americans still lack access to it

Why drug prescriptions should include diagnoses

Sports medicine is finally prioritizing gender equality

Canadians with cystic fibrosis outlive Americans by a decade

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

UpToDate has a racism problem: Dr. Stanley Goldfarb

Duchenne breakthrough therapy leaves behind pioneering families

Do masks work? RCTs can't tell us

Wikipedia

Canadians with cystic fibrosis outlive Americans by a decade

Vertex cell therapy lets patients with type 1 diabetes stop insulin

The strategy behind pharma's lawsuits over drug pricing reform

In areas with more Black doctors, Black people live longer

The wait for US passports is creating travel purgatory and snarling summer plans

Fatty liver disease was alleviated by Lilly’s ‘triple

entertainment

entertainment

explore

hotspot